Headlines about Zosano Pharma (NASDAQ:ZSAN) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.4927349617371 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern’s scoring:
- Issuance Will Extend Patent Life of M207 to 2037 (einpresswire.com)
- Analysts’ Report Recap – Zosano Pharma Corporation (NASDAQ: ZSAN) – The Investor Guide (wallstreetnews24.com)
- Zosano Pharma (ZSAN) Announces Notice of Allowance for US Patent Application Covering M207 as Acute Treatment … – StreetInsider.com (streetinsider.com)
- Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine (finance.yahoo.com)
Separately, ValuEngine upgraded Zosano Pharma from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st.
Zosano Pharma (NASDAQ:ZSAN) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). research analysts anticipate that Zosano Pharma will post -0.9 earnings per share for the current fiscal year.
In related news, Director Kenneth Greathouse acquired 95,000 shares of Zosano Pharma stock in a transaction that occurred on Friday, December 1st. The stock was acquired at an average price of $0.62 per share, for a total transaction of $58,900.00. Following the transaction, the director now directly owns 95,000 shares of the company’s stock, valued at approximately $58,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have purchased a total of 200,000 shares of company stock valued at $123,450 in the last 90 days. Insiders own 2.83% of the company’s stock.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.